Edition:
United Kingdom

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

14.55USD
23 Feb 2018
Change (% chg)

$1.90 (+15.02%)
Prev Close
$12.65
Open
$13.95
Day's High
$14.87
Day's Low
$13.95
Volume
1,429
Avg. Vol
1,256
52-wk High
$17.50
52-wk Low
$10.44

Chart for

About

Verona Pharma plc is a United Kingdom-based clinical-stage biopharmaceutical company. The principal activity of the Company is the development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. The Company's product candidate, RPL554, is a... (more)

Overall

Beta: 1.05
Market Cap(Mil.): £149.65
Shares Outstanding(Mil.): 105.02
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 83.93 16.60
EPS (TTM): -- -- --
ROI: -- 1.66 10.66
ROE: -- 2.58 14.30

BRIEF-Verona Pharma Expects To Report Top-Line Data From Phase 2b Trial Of Nebulized RPl554​ Early In Q2

* VERONA PHARMA PLC - ‍ANTICIPATES REPORTING TOP-LINE DATA FROM ITS PHASE 2B TRIAL EARLY IN Q2 OF 2018 FOR NEBULIZED RPL554​

13 Feb 2018

BRIEF-Verona Pharma announces positive top-line data from Phase 2A clinical trial in COPD with RPL554 dosed in addition to Tiotropium

* ANNOUNCES POSITIVE TOP-LINE DATA FROM PHASE 2A CLINICAL TRIAL IN COPD WITH RPL554 DOSED IN ADDITION TO TIOTROPIUM (SPIRIVA) Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

07 Sep 2017

Earnings vs. Estimates